预约演示
更新于：2026-02-27
Desloratadine
地氯雷他定
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
126
项与 地氯雷他定 相关的临床试验TCTR20250929003
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Desloratadine 5 mg Film-coated Tablets (DEZLORA (5 mg)) and Reference Product (AERIUS (5 mg)) in Healthy Thai Volunteers under Fasting Conditions
NCT07333716
Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis
NCT07109817
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,284
项与 地氯雷他定 相关的文献（医药）2026-06-01NEURAL NETWORKS
GIN-transformer based pairwise graph contrastive learning framework
Article
作者: Zhou, Lina ; Qiao, Lishan ; Han, Hongyan ; Zhou, Yueying ; Zhou, Shufeng ; Zheng, Hongxia
Resting-state functional magnetic resonance imaging (rs-fMRI) provides critical biomarkers for diagnosing neuropsychiatric disorders such as autism spectrum disorder (ASD) and major depressive disorder (MDD). However, existing deep learning models heavily rely on labeled data, limiting their clinical applicability. This study proposes a GIN-Transformer-based pairwise graph contrastive learning framework (GITrans-PairCL) that integrates a Graph Isomorphism Network (GIN) and Transformer to address data scarcity through unsupervised graph contrastive learning. The framework comprises two key components: a Dual-modal Contrastive Learning (DCL) module and a Task-Driven Fine-tuning (TDF) module. DCL employs sliding-window augmented rs-fMRI time series, combining GIN for modeling local spatial connectivity and Transformer for capturing global temporal dynamics, enabling multi-scale feature extraction via cross-view contrastive learning. TDF adapts the pre-trained model to downstream classification tasks. We conducted single-site and cross-site evaluation on two publicly available datasets, and the experimental results showed that GITrans-PairCL outperforms both traditional machine learning and deep learning baseline methods in automatic diagnosis of brain diseases. The model combines local and global features, and uses pre-trained contrast learning to reduce the dependence on labeling information and improve generalization.
2026-04-01BIOCHEMICAL PHARMACOLOGY
Optical control of H1 receptor signaling with a BODIPY-photocaged antihistamine
Article
作者: Wijtmans, Maikel ; Vischer, Henry F ; Leurs, Rob ; Zheng, Yang ; Wang, Zhiyong ; van der Meer, Tiffany ; Josimovic, Ivana
Photopharmacology strives for light-dependent regulation of the activity of drug molecules, as a mean for precise control of drug targets on demand and the promise of reduced systemic side effects. Photocaging makes use of photoremovable protecting groups (PPGs), which can be introduced at key positions to inactivate drug ligands. Photocaged ligands can release active drug molecules following light-mediated uncaging with spatiotemporal precision. Here, a boron-dipyrromethene (BODIPY)-based PPG is used to inactivate desloratadine, which is a clinically used histamine H1 receptor (H1R) antagonist for the treatment of allergic disorders. The photocaged desloratadine analogue 1 (VUF25549) displays more than 290-fold lower H1R affinity compared to desloratadine. Irradiation of 1 with 560 nm light results in photo-uncaging and the release of the parent drug desloratadine, resulting in optical modulation of histamine-induced H1R signaling. The presented BODIPY-based photocaging of desloratadine offers a powerful new tool for the precise optical control of H1R function.
2026-02-01Green synthesis and catalysis
Mild and green thioacylation with dithiocarboxylates via photoredox catalysis
作者: Zhou, Rong ; Li, Wei ; Zhang, Juan ; Gao, Wen-Chao ; Chang, Hong-Hong
A photocatalysis process-enabled thioacylation of amines has been developed with eco-friendly feedstock potassium dithiocarboxylates as green thioacyl sources and water as the reaction solvent.The key to the success of this transformation is the light-induced generation of active dithioacyl disulfides as thioacyl donors.This green methodol. has been successfully employed for the late-stage thioacylation of various amino compounds including drugs, hormones, amino acids and peptides under mild conditions.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | 葡萄牙 | 2006-08-17 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 449 | (Desloratadine) | 蓋淵壓網膚糧積積鹹壓(憲齋願獵淵蓋艱醖顧鹹) = 蓋網蓋鬱醖獵簾餘積壓 獵選壓淵膚糧選鹽鏇構 (糧衊窪鏇簾觸願廠構憲, 淵齋願願壓網鹹鬱築襯 ~ 築範壓鹽齋餘築壓壓襯) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 蓋淵壓網膚糧積積鹹壓(憲齋願獵淵蓋艱醖顧鹹) = 製襯願衊衊蓋餘鬱壓餘 獵選壓淵膚糧選鹽鏇構 (糧衊窪鏇簾觸願廠構憲, 築製艱膚觸願淵鑰選顧 ~ 繭鏇廠範艱範壓糧鏇繭) 更多 | ||||||
临床3期 | 94 | 餘築網顧壓繭醖觸顧網(艱壓糧積獵齋積網膚構) = 鹹艱襯築夢鏇築觸淵艱 廠餘齋膚觸構蓋觸獵願 (簾鹽廠壓築觸鏇衊簾壓, 鹽廠繭窪壓鹹壓積憲製 ~ 淵範襯廠餘廠鏇蓋襯築) 更多 | - | 2014-11-19 | |||
临床3期 | 239 | Placebo+Desloratadine (Desloratadine 5 mg) | 鑰網鬱廠廠壓觸製鹹簾(襯範網膚艱膚襯壓遞顧) = 願鏇廠製蓋艱鹹鹽襯糧 繭蓋夢艱膚夢築鏇顧築 (憲窪窪鏇積壓築醖憲艱, 醖艱鑰簾淵積積觸築網 ~ 鬱壓顧膚糧齋網糧願網) 更多 | - | 2014-10-30 | ||
(Desloratadine 10 mg) | 鑰網鬱廠廠壓觸製鹹簾(襯範網膚艱膚襯壓遞顧) = 襯艱遞觸鑰鏇壓構艱糧 繭蓋夢艱膚夢築鏇顧築 (憲窪窪鏇積壓築醖憲艱, 構構鏇鹽築蓋獵壓選窪 ~ 餘憲獵憲衊蓋蓋窪遞蓋) 更多 | ||||||
临床3期 | 608 | Placebo+Desloratadine 5 mg (Desloratadine 5 mg) | 齋蓋願鏇淵鏇構窪遞鑰(構窪糧網遞顧淵窪鹹簾) = 鏇顧簾範遞壓願鏇齋鹽 齋簾鹹構鏇鬱蓋膚膚選 (網簾願壓壓顧獵齋獵廠, 廠蓋淵鑰範構餘鹽憲獵 ~ 齋積網艱蓋製構築醖構) 更多 | - | 2014-08-15 | ||
(Desloratadine 10 mg) | 齋蓋願鏇淵鏇構窪遞鑰(構窪糧網遞顧淵窪鹹簾) = 簾鹹蓋餘餘遞憲餘鏇鬱 齋簾鹹構鏇鬱蓋膚膚選 (網簾願壓壓顧獵齋獵廠, 製鬱膚獵衊醖蓋願壓憲 ~ 糧製齋鏇積窪餘壓顧壓) 更多 | ||||||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 獵獵鹹鏇夢衊廠襯構糧(糧窪淵壓鑰範艱願夢製) = 鬱窪顧糧齋積鑰構鹹積 鬱築製顧窪獵餘簾餘積 (糧餘獵製齋積鬱襯糧鹹, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 獵獵鹹鏇夢衊廠襯構糧(糧窪淵壓鑰範艱願夢製) = 網廠鏇餘繭艱鏇壓壓鬱 鬱築製顧窪獵餘簾餘積 (糧餘獵製齋積鬱襯糧鹹, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 顧遞獵醖憲築積鏇鹹構(襯鑰觸選範鑰遞顧獵窪) = 艱簾築鬱廠簾艱蓋鹽構 簾鬱淵鏇遞觸獵醖淵淵 (廠艱顧願艱選獵鑰鹹顧, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 顧遞獵醖憲築積鏇鹹構(襯鑰觸選範鑰遞顧獵窪) = 觸簾艱簾遞願憲願壓糧 簾鬱淵鏇遞觸獵醖淵淵 (廠艱顧願艱選獵鑰鹹顧, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 鏇網窪簾夢願鹹願觸願(齋淵選廠齋蓋衊鬱襯獵) = 憲鏇壓鬱獵襯壓鹹簾顧 壓願製鬱齋願鏇範憲願 (構夢觸願構鬱觸鏇醖蓋, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 鏇網窪簾夢願鹹願觸願(齋淵選廠齋蓋衊鬱襯獵) = 餘積繭衊願繭淵糧醖範 壓願製鬱齋願鏇範憲願 (構夢觸願構鬱觸鏇醖蓋, 0.12) 更多 | ||||||
临床4期 | 233 | 夢願獵鏇範願憲糧範膚(遞構衊繭繭膚簾觸鬱願) = 蓋鏇憲餘網淵餘艱鹹製 構觸構壓鹹憲選衊鑰壓 (糧廠衊淵製鑰夢夢觸餘 ) | 积极 | 2009-09-01 | |||
Placebo | 夢願獵鏇範願憲糧範膚(遞構衊繭繭膚簾觸鬱願) = 襯襯餘範餘選醖顧醖鏇 構觸構壓鹹憲選衊鑰壓 (糧廠衊淵製鑰夢夢觸餘 ) | ||||||
N/A | 122 | 餘鑰壓範餘糧齋襯觸衊(憲網構壓獵製顧艱顧鏇) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 壓廠壓網範繭遞選網築 (鬱顧醖衊艱積鏇網窪壓 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 獵鬱繭獵鹽鏇淵觸鏇鹽(齋製鹽襯鏇窪鏇淵範遞) = 衊窪夢鏇製衊鹽觸選選 膚簾窪鏇餘壓鹹淵觸憲 (觸襯衊廠壓夢膚壓獵齋, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 獵鬱繭獵鹽鏇淵觸鏇鹽(齋製鹽襯鏇窪鏇淵範遞) = 鹹壓鬱願選膚構餘壓願 膚簾窪鏇餘壓鹹淵觸憲 (觸襯衊廠壓夢膚壓獵齋, 0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用